Ocean Biomedical congratulates joint venture partner Virion Therapeutics

Ocean Biomedical congratulates its JV partner Virion Therapeutics on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure, at the EASL 2024 Congress, taking place in Milan, Italy from June 5 – 8. The late breaker Phase 1b data presented, which includes Virion’s first checkpoint modifier, glycoprotein D, demonstrated that VRON-0200 was not only safe and well tolerated, but immunogenic in the majority of chronically HBV-infected patients, following a single intramuscular injection. “Chronic HBV infection severely impairs a patient’s ability to clear the virus. A single low dose injection of VRON-0200 was able to stimulate T cell responses in the majority of patients, most of whom had little, to no, documented HBV immunity prior to treatment” said Virion’s CEO, Dr. Andrew Luber. Luber added, “VRON-0200 is our lead clinical program and these clinical safety and immunogenicity data will further support our proprietary platform technologies and other pipeline programs in development, including VRON-0300, which is for patients with advanced solid tumors.”